155 related articles for article (PubMed ID: 19706807)
21. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
[TBL] [Abstract][Full Text] [Related]
22. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
Kurata T; Tsurutani J; Fujisaka Y; Okamoto W; Hayashi H; Kawakami H; Shin E; Hayashi N; Nakagawa K
Invest New Drugs; 2014 Oct; 32(5):946-54. PubMed ID: 24875132
[TBL] [Abstract][Full Text] [Related]
24. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Inoue K; Kuroi K; Shimizu S; Rai Y; Aogi K; Masuda N; Nakayama T; Iwata H; Nishimura Y; Armour A; Sasaki Y
Int J Clin Oncol; 2015 Dec; 20(6):1102-9. PubMed ID: 25967286
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
[TBL] [Abstract][Full Text] [Related]
27. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
32. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; DiƩras V
Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115
[TBL] [Abstract][Full Text] [Related]
33. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Di Leo A; Gomez HL; Aziz Z; Zvirbule Z; Bines J; Arbushites MC; Guerrera SF; Koehler M; Oliva C; Stein SH; Williams LS; Dering J; Finn RS; Press MF
J Clin Oncol; 2008 Dec; 26(34):5544-52. PubMed ID: 18955454
[TBL] [Abstract][Full Text] [Related]
34. Analysis of dermatologic events in patients with cancer treated with lapatinib.
Lacouture ME; Laabs SM; Koehler M; Sweetman RW; Preston AJ; Di Leo A; Gomez HL; Salazar VM; Byrne JA; Koch KM; Blackwell KL
Breast Cancer Res Treat; 2009 Apr; 114(3):485-93. PubMed ID: 18600445
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Gong JF; Lu M; Li J; Li Y; Zhou J; Lu ZH; Wang XC; Li J; Zhang XT; Shen L
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Feb; 46(1):144-8. PubMed ID: 24535367
[TBL] [Abstract][Full Text] [Related]
36. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
[TBL] [Abstract][Full Text] [Related]
37. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Chien AJ; Munster PN; Melisko ME; Rugo HS; Park JW; Goga A; Auerback G; Khanafshar E; Ordovas K; Koch KM; Moasser MM
J Clin Oncol; 2014 May; 32(14):1472-9. PubMed ID: 24711549
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]